Notice: This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends AQXP vs. SDGR, NAMS, DVAX, GERN, BLTE, TVTX, IRON, WVE, EVO, and PRAXShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Schrödinger (SDGR), NewAmsterdam Pharma (NAMS), Dynavax Technologies (DVAX), Geron (GERN), Belite Bio (BLTE), Travere Therapeutics (TVTX), Disc Medicine (IRON), Wave Life Sciences (WVE), Evotec (EVO), and Praxis Precision Medicines (PRAX). These companies are all part of the "medical" sector. Aquinox Pharmaceuticals vs. Schrödinger NewAmsterdam Pharma Dynavax Technologies Geron Belite Bio Travere Therapeutics Disc Medicine Wave Life Sciences Evotec Praxis Precision Medicines Schrödinger (NASDAQ:SDGR) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability. Does the MarketBeat Community prefer SDGR or AQXP? Aquinox Pharmaceuticals received 245 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 71.88% of users gave Aquinox Pharmaceuticals an outperform vote while only 57.45% of users gave Schrödinger an outperform vote. CompanyUnderperformOutperformSchrödingerOutperform Votes5457.45% Underperform Votes4042.55% Aquinox PharmaceuticalsOutperform Votes29971.88% Underperform Votes11728.13% Do analysts prefer SDGR or AQXP? Schrödinger currently has a consensus target price of $32.11, suggesting a potential upside of 41.83%. Given Schrödinger's stronger consensus rating and higher probable upside, research analysts clearly believe Schrödinger is more favorable than Aquinox Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrödinger 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80Aquinox Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk and volatility, SDGR or AQXP? Schrödinger has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -7.37, suggesting that its share price is 837% less volatile than the S&P 500. Which has preferable valuation and earnings, SDGR or AQXP? Schrödinger has higher revenue and earnings than Aquinox Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrödinger$216.67M7.61$40.72M-$2.34-9.68Aquinox Pharmaceuticals$25M16.35-$31.58MN/AN/A Is SDGR or AQXP more profitable? Aquinox Pharmaceuticals has a net margin of 0.00% compared to Schrödinger's net margin of -91.84%. Aquinox Pharmaceuticals' return on equity of -30.13% beat Schrödinger's return on equity.Company Net Margins Return on Equity Return on Assets Schrödinger-91.84% -35.77% -24.51% Aquinox Pharmaceuticals N/A -30.13%-28.08% Does the media prefer SDGR or AQXP? In the previous week, Schrödinger had 4 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 4 mentions for Schrödinger and 0 mentions for Aquinox Pharmaceuticals. Schrödinger's average media sentiment score of 0.68 beat Aquinox Pharmaceuticals' score of 0.00 indicating that Schrödinger is being referred to more favorably in the media. Company Overall Sentiment Schrödinger Positive Aquinox Pharmaceuticals Neutral Do institutionals and insiders hold more shares of SDGR or AQXP? 79.1% of Schrödinger shares are owned by institutional investors. Comparatively, 71.7% of Aquinox Pharmaceuticals shares are owned by institutional investors. 8.6% of Schrödinger shares are owned by insiders. Comparatively, 4.0% of Aquinox Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummarySchrödinger beats Aquinox Pharmaceuticals on 12 of the 17 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$408.65M$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A6.1126.7019.17Price / Sales16.35268.31435.2970.71Price / CashN/A65.6738.0134.83Price / Book5.626.707.644.62Net Income-$31.58M$138.98M$3.19B$246.06M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$17.36+0.3%N/A-41.9%$408.65M$25M0.008SDGRSchrödinger1.9401 of 5 stars$25.18-1.9%$32.11+27.5%-24.6%$1.83B$216.67M-10.76790Upcoming EarningsNAMSNewAmsterdam Pharma3.283 of 5 stars$19.26-4.6%$41.60+116.0%-13.9%$1.78B$14.09M0.004Upcoming EarningsDVAXDynavax Technologies4.2783 of 5 stars$13.20+0.4%$23.00+74.2%+7.0%$1.74B$232.28M101.55350Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpGERNGeron3.015 of 5 stars$2.82-3.8%$7.25+157.1%+33.4%$1.70B$240,000.00-8.8170Analyst ForecastAnalyst RevisionNews CoverageBLTEBelite Bio3.2199 of 5 stars$53.80-6.5%$96.33+79.1%+26.3%$1.66BN/A-48.4710TVTXTravere Therapeutics2.955 of 5 stars$21.10-3.0%$24.00+13.7%+178.9%$1.65B$145.24M-4.64460Earnings ReportAnalyst ForecastNews CoverageGap DownIRONDisc Medicine1.8724 of 5 stars$54.71-0.2%$88.90+62.5%-15.9%$1.63BN/A-13.7530Insider TradeNews CoverageWVEWave Life Sciences4.3638 of 5 stars$10.66-4.6%$22.22+108.5%+178.9%$1.63B$53.61M-9.60240Positive NewsGap UpEVOEvotec1.7817 of 5 stars$4.52+1.6%$5.93+31.3%-39.5%$1.60B$845.74M0.005,061PRAXPraxis Precision Medicines1.9403 of 5 stars$84.85-2.3%$149.00+75.6%+84.0%$1.58B$2.45M-8.24110 Related Companies and Tools Related Companies SDGR Competitors NAMS Competitors DVAX Competitors GERN Competitors BLTE Competitors TVTX Competitors IRON Competitors WVE Competitors EVO Competitors PRAX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AQXP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
